高敏肌钙蛋白与2021年急性胸痛评估与诊断指南
2021年AHA/ACC等多学会急性胸痛指南推荐高敏肌钙蛋白(hs-cTn)为首选生物标志物,以99百分位上限定义心肌损伤,并倡导临床决策路径。本文解读hs-cTn检测限与定量限、单样本策略、99百分位上限推导、性别特异值、浓度变化(delta)用于诊断与危险分层,以及如何与临床决策路径整合。
要点
- hs-cTn是急性胸痛评估的首选生物标志物,99百分位上限用于定义心肌损伤。
- 临床需理解hs-cTn检测限与定量限,尤其单样本策略排除急性心肌梗死时。
- 利用hs-cTn浓度变化(delta)可辅助诊断与危险分层,并鉴别急性与慢性心肌损伤。
核心结论
- 2021年多学会急性胸痛指南推荐hs-cTn为首选生物标志物,并以99百分位上限定义心肌损伤。
- 临床应掌握hs-cTn分析特性、性别特异99百分位上限及浓度变化,并与临床决策路径整合。
研究设计与样本
- 指南制定机构包括AHA、ACC、ASE、CHEST、SAEM、SCCT和SCMR。
主要发现
- 指南认可女性及其他患者亚群的独特性。
- 使用hs-cTn后,2型心肌梗死诊断更常见,不稳定型心绞痛更少见但仍发生。
关键数值与推荐
- 推荐hs-cTn为首选生物标志物,并以99百分位上限定义心肌损伤。
- 推荐使用临床决策路径评估急性胸痛。
- 需关注hs-cTn检测限与定量限,尤其单样本策略排除急性心肌梗死时。
- 应理解99百分位上限的推导及性别特异99百分位上限的价值。
- 利用hs-cTn浓度变化(delta)辅助诊断与危险分层,鉴别急性与慢性心肌损伤。
临床怎么用
- 临床应优先使用hs-cTn检测,并按99百分位上限判读心肌损伤。
- 应用临床决策路径结合hs-cTn系列检测或单样本策略评估急性胸痛。
- 注意性别特异99百分位上限,并利用浓度变化鉴别急慢性心肌损伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 2021 American Heart Association/American College of Cardiology/American Society of Echocardiography/American College of Chest Physicians/Society for Academic Emergency Medicine/Society of Cardiovascular Computed Tomography/Society for Cardiovascular Magnetic Resonance guidelines for the evaluation and diagnosis of acute chest pain make important recommendations that include the recognition of high-sensitivity cardiac troponin (hs-cTn) as the preferred biomarker, endorsement of 99th percentile upper reference limits to define myocardial injury, and the use of clinical decision pathways, as well as acknowledgment of the uniqueness of women and other patient subsets. Details on how to integrate hs-cTn into clinical practice are less extensively addressed. Clinicians should be aware of some of the analytical aspects related to hs-cTn assays regarding the limit of detection and the limit of quantitation and how they are used clinically, especially for the single sample strategy to rule out acute myocardial infarction. Likewise, it is important for clinicians to understand issues related to the derivation of the 99th percentile upper reference limit; the value of sex-specific 99th percentile upper reference limits; how to use changing concentrations (deltas) to facilitate diagnosis and risk stratification of patients with suspected acute coronary syndrome, including the differentiation of acute from chronic myocardial injury; and how to best integrate the use of hs-cTn with clinical decision pathways. With the use of hs-cTn, conditions such as type 2 myocardial infarction become more common, whereas others such as unstable angina become less frequent but still occur. Sections relating to these issues are included.
引用
- Sandoval, Apple, Mahler, et al. High-Sensitivity Cardiac Troponin and the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain. Circulation. 2022. PMID: 35775423. doi:10.1161/CIRCULATIONAHA.122.059678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。